[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
Confi
dential/Proprietary Information  
Page 1 of 69 Title Page 
Protocol Title:  
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 
84 Years  
Study Code: PSK00009 
Protocol Version Number:  3.0 
Amendment Number: 1 
Compound: 21-valent pneumococcal conjugate vaccine, SP0202 
Study Phase:  II 
Short Title:  
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Y ears. 
Sponsor Name [CONTACT_29560]:  
[COMPANY_011] Pasteur Inc. Discovery Drive, Swiftwater, PA [ZIP_CODE], US 
Manufacturer:  
SK Bioscience CO., Ltd. 
310 Pangyo-ro, Bundang-gu, Seongnami-si, Gyeonggi-do, [ZIP_CODE], South Korea  
Regulatory Agency Identifier Number(s) : 
BB-IND:  018207 
Approval Date:  [ADDRESS_28772] Information are provided in the Operating Guidelines. 
The study centers, the Investigators at each center , and the Coordinating Investigators are listed in 
a separate docu ment . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 1 of 70[STUDY_ID_REMOVED]
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 2 of 69 Document History 
 
Previous 
Version  Date Comments  
1.0 26 May 2020  Version submitted and  approved by [CONTACT_1744] / IEC.  
Updated in response to comments provided by [CONTACT_29486] (CBER) prior to study initiation.  
2.[ADDRESS_28773] version used in the study  at the time of FVFS  
IRB: Institutional Review Board; IEC: Independent Ethics Committee  
Overall Rationale for the Amendment:  
The study has been amended to add a Data Monitoring Committee (DMC) review . An unblinded 
review will be  performed by [CONTACT_29487] [ADDRESS_28774] safety data up to 30 days after injection available . The results from this DMC review will be 
supportive to the Sponsor decision- making process as regards to the SP0202 clinical development 
plan. 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 2 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28775] of Figures  .................................................................................................................................. 8  
1 Protocol Summary ............................................................................................................. 9  
1.1 Synopsis ............................................................................................................................ 9  
1.2 Schema  ............................................................................................................................ 11  
1.3 Schedule of Activities (SoA) .......................................................................................... 12  
2 Introduction ..................................................................................................................... 14  
2.1 Study Rationale ............................................................................................................... 14  
2.2 Background ..................................................................................................................... 15  
2.3 Benefit/Risk Assessment  ................................................................................................ 16  
2.3.1  Risks from Study Participation ..................................................................................... 17  
2.3.2  Benefits from Study Participation  ................................................................................ 18  
2.3.3  COVID- 19 risk assessment  .......................................................................................... 18  
2.3.4  Overall Benefit -Risk Conclusion .................................................................................. 18  
3 Objectives and Endpoints  ............................................................................................... 19  
4 Study Design .................................................................................................................... 20  
4.1 Overall Design  ................................................................................................................ 20  
4.2 Scientific Rationale for Study Design  ............................................................................. 20  
4.3 Justification for Dose  ...................................................................................................... 21  
4.4 End of Study Definition .................................................................................................. 21  
5 Study Population  ............................................................................................................. 22  
5.1 Inclusion Criteria  ............................................................................................................ 22  
5.2 Exclus ion Criteria  ........................................................................................................... 22  
5.3 Lifestyle Considerations  ................................................................................................. 24  
5.4 Screen Failures  ................................................................................................................ 24  
6 Study Intervention  ........................................................................................................... 24  
6.1 Study Intervention(s) Administered  ................................................................................ 24  
6.2 Preparation/Handling/Storage/Accountability  ................................................................ 26  
6.3 Measures to Minimize Bias: Randomization and Blinding  ............................................ 27  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 3 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 4 of 69 6.3.1  Randomization and Allocation Procedures .................................................................. 27  
6.3.2  Blinding and Code-breaking Procedures ...................................................................... 27  
6.4 Study Intervention Compliance ...................................................................................... 29  
6.5 Concomitant Therapy ...................................................................................................... 29  
6.5.1  Rescue Medicine  ........................................................................................................... 30  
6.6 Dose Mod ification  .......................................................................................................... 30  
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  .......................................................................................... 31  
7.1 Discontinuation of Study Intervention ............................................................................ 31  
7.1.1  Temporary contraindications ........................................................................................ 31  
7.2 Participant Discontinuation/Withdrawal from the Study  ................................................ [ADDRESS_28776]  ............................................................................... 37  
8.4 Treatment of Overdose ................................................................................................... 38  
8.5 Pharmacokinetics ............................................................................................................ 38  
8.6 Pharmacodynamics ......................................................................................................... 38  
8.7 Genetics  ........................................................................................................................... 38  
8.8 Biomarkers  ...................................................................................................................... 38  
8.9 Immunogenicity Assessments ......................................................................................... 38  
8.10  Medical Resource Utilization and Health Economics .................................................... 38  
9 Statistical Considerations  ............................................................................................... 38  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 4 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 5 of 69 9.1 Statistical Hypotheses  ..................................................................................................... 38  
9.2 Sample Size Determination  ............................................................................................. 39  
9.3 Populations for Analyses  ................................................................................................ 39  
9.4 Statistical Analyses  ......................................................................................................... 40  
9.4.1  General Considerations  ................................................................................................. 40  
9.4.2  Safety Analyses  ............................................................................................................ 41  
9.4.3  Immunogenicity Analyses ............................................................................................ 41  
9.4.4  Other Analyses  ............................................................................................................. 42  
9.5 Interim Analyses ............................................................................................................. 42  
9.6 Data Monitoring Committee (DMC) .............................................................................. 42  
10 Supporting Documentation and Operational Considerations  .................................... 43  
10.1  Appendix: Regulatory, Ethical, and Study Oversight Considerations  ............................ 43  
10.1.1  Regulatory and Ethical Considerations ........................................................................ 43  
10.1.2  Financial Disclosure  ..................................................................................................... 44  
10.1.3  Informed Consent Process ............................................................................................ 44  
10.1.4  Data Protection and Future Use of Stored Samples ..................................................... 45  
10.1.5  Committees Structure  ................................................................................................... 46  
10.1.6  Dissemination of Clinical Study Data .......................................................................... 46  
10.1.7  Data Quality Assurance  ................................................................................................ 46  
10.1.8  Source Documents ........................................................................................................ 47  
10.1.9  Study and Site Start and Closure .................................................................................. 47  
10.1.10  Publication Policy  ......................................................................................................... 48  
10.2  Appendix: Clinical Laboratory Tests .............................................................................. 48  
10.3  Appendix: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................................ 48  
10.3.1  Definition of AE  ........................................................................................................... 49  
10.3.2  Definition of SAE  ......................................................................................................... 51  
10.3.3  Recording and Follow-Up of AE and/or SAE .............................................................. 52  
10.3.4  Reporting of SAEs ........................................................................................................ 54  
10.3.5  Assessment of Intensity  ................................................................................................ 55  
[IP_ADDRESS]  Tables for Clinical Abnormalities  .............................................................................. 55  
[IP_ADDRESS].1  Solicited AR Intensity Grading Scale  ...................................................................... 55  
[IP_ADDRESS].2  Unsolicited AE Intensity Grading Scale  .................................................................. 61  
10.4  Appendix: Collection of Pregnancy Information ............................................................ 61  
10.5  Appendix: Risk- based Approach .................................................................................... 63  
10.6  Appendix: Abbreviations ................................................................................................ 64  
10.7  Appendix: Protocol Amendment History ....................................................................... 66  
11 References  ........................................................................................................................ 67  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 5 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 6 of 69 12 Sponsor Signature [CONTACT_3490]  .................................................................................................. 69  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 6 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28777] of Tables  
Table  1.1: Schedule of activities ................................................................................................... 12  
Table  2.1: Specificities of the 4 formulations evaluated in Phase I study PSK00007 .................. 14  
Table  2.2: Potential risks of clinical significance and risk management  ...................................... 17  
Table  3.1: Objectives and endpoints ............................................................................................. 19  
Table  4.1: Overall design  .............................................................................................................. 20  
Table  6.1: Identity of study intervention(s) ................................................................................... 25  
Table  10.1: Solicited injection site reactions: terminology, definitions, and intensity scales ....... 56  
Table  10.2: Solicited systemic reactions: terminology, definitions, and intensity scales ............. 58  
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 7 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28778] of Figures  
Figure 1.1: Graphical study design ................................................................................................ 11  
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 8 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 9 of 69 1 Protocol Summary 
1.1 Synopsis 
Protocol Title:  
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 
84 Y ears 
Short Title:  
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years 
Rationale: 
The SP0202 investigational vaccine is intended to provide protection against diseases caused by 
[CONTACT_29488], in  population from infants to 
elderly . There are two types  of pneumococcal vaccines available in the [LOCATION_002]: Prevnar 13 
(a 13- valent conjugated vaccine) and Pneumovax 23 (a 23-valent unconjugated vaccine). Both 
vaccines are recommended in  the US  population aged 65 years or above (1) . SP0202 
investigational vaccine contains 21 serotypes that are conjugated to  carrier protein . PSK00009 is a 
Phase II study that will evaluate the immunogenicity and safety of 3 SP0202 formulations that 
differ by [CONTACT_29489] a few serotypes , administered as a single dose to healthy adults 
aged 50 to 84 years. Two groups will serve as control and receive a single dose of either Prevnar 13 or Pneumovax 23. 
Objectives and Endpoints:  
Objectives  Endpoints  
Immunogenicity  
To assess the immune response of the 
3 SP0202 formulations, Prevnar  13, 
and Pneumovax 23 30 days after the  
administration of the single dose vaccination • Serotype specific OPA titers for all pneumococcal 
serotypes included in the SP0202 formulations, as 
determined by [CONTACT_29490] (MOPA), at baseline (D01)  and 30 days after 
vaccination (D31)  
• Serotype specific OPA titers ratio (post/pre-injection) for all pneumococcal serotypes included in the SP0202 formulations as determined by [CONTACT_29491] 
• Serotype -specific IgG concentrations for all 
pneumococcal serotypes included in the SP0202 formulations as measured by [CONTACT_29492]-chemiluminescence assay (ECL), at baseline (D01)  and 30 days after 
vaccination (D31)  
• Serotype -specific IgG concentration ratios 
(post/pre -vaccination) for all pneumococcal serotypes 
included in the SP0202 formulations as measured by [CONTACT_29493]/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 9 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 10 of 69 Safety 
To assess the safety profile of the 3 
SP0202 formulations, Prevnar 13, and Pneumovax 23 • Presence of any unsolicited systemic AEs reported in 
the 30 minutes after injection of a SP0202 formulation, Prevnar  13, or Pneumovax 23  
• Presence of solicited (ie, pre -listed in the participant’s 
DC and in the case report form (CRF)) injection site 
reactions occurring up to 7 days after the day of 
injection (D0 8) of a SP0202 formulation, Prevnar  13, 
or Pneumovax 23  
• Presence of solicited (ie, pre -listed in the participant’s 
DC and in the CR F) systemic reactions occurring up to 
7 days after the day of injection  (D08) of a SP0202 
formulation, Pr evnar 13, or Pneumovax 23  
• Presence of unsolicited (spontaneously reported) AEs up to 30 days after the day of  injection (D31) of a 
SP0202 formulation, Prevnar  13, or Pneumovax 23  
• Presence of SAEs and AESIs, throughout the study 
period (up to 6-month follow -up) 
 
Overall Design  
Type of design  Parallel, multi center  (approximately 8 sites)  
Phase  II 
Control method  Active -controlled  
(controls = Prevnar  13 and Pneumovax 23) 
Study population  Healthy adults aged 50 to 84 years  
Countries  United State s of America  
Level and method of blinding  Modified double -blind  (observer -blind)  
Study intervention assignment method  Randomization  with stratification by [CONTACT_29494] (ie 50 -64 years and 65 to 84 years)  
Review group  Safety Management Team (SMT) and Data 
Monitoring Committee  
 
Disclosure Statement : 
This is a parallel group prevention study with 5 groups that is Participant , Investigator and 
Outcomes Assessor blinded.  
Number of Participant s: 
A total of 750 participants, approximatively 150 in each group (approximately 375 participants 
aged 50 to 64 years and 375 participants aged 65 to 84 years) are expected to be randomized. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 10 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 11 of 69 Group  Number of 
Participants  Formulation Name  
[CONTACT_26374] 1  150 SP0202-IIb  
Group 2  150 SP0202-VI  
Group 3  150 SP0202-VII  
Group 4  150 Prevnar 13® 
Group 5 150 Pneumovax 23® 
 
Intervention Groups and Duration:  
Eligible participants will be randomized in a 1:1:1:1:1 ratio to receive a single intramuscular (IM) 
injection of either 1 of the 3 SP0202 formulations or Prevnar 13 or Pneumovax 23 at Day (D)01. 
The duration of each participant’s  participation will be approximately  6 months. 
Data Monitoring Committee : Yes 
1.2 Schema  
The graphical design of PSK00009 study is presented in Figure  1.1. 
Figure  1.1: Graphical study design  
 
BL: Blood sample 
VAC:  vaccination 
TC: telephone call  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 11 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 12 of 69  
1.3 Schedule of Activities (SoA)  
Visits procedures are detailed in the Operating Guidelines.  
Table  1.1: Schedule of activities  
Phase II Study, 2 Visits, 1 Phone Call, 1 Vaccination, 2 Blood Samples, Approximately 6 
Months Duration Per Participant  
Visit/Contact  [CONTACT_29495] 1  Visit 2 * Phone call 
6-month safety 
follow -up 
Study timelines (days)   D01 D31 D181  
Time windows (days)   NA [+14  D] +14 
Visit procedures:      
Informed consent  X X   
Inclusion/exclusion criteria  X X   
Collection of demographic data † X X   
Urine pregnancy test (if applicable) ‡  X   
Collection of Medical history X 
Significant  
Medical History  X   
Physical examination (including body 
temperature) §  X X  
Randomization/allocation of 
participant number  X X   
Blood sampling (BL), 20 mL  X BL0001  
Pre-vac  BL0002   
Vaccination (vac)  X X   
Immediate surveillance (30 min)  X X   
Diary card provided **  X   
Collection of solicited injection site 
and systemic reactions  X D01 – D08   
Collection of unsolicited adverse 
events (AEs)  X To be reported at any 
time from D01 to D31  
Diary card reviewed and collected    X ††  
Memory aid provided    X  
Telephone call    X 
Memory aid reviewed     X‡‡ 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 12 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28779] (AESIs)  X To be reported at any time during the 
study  
Collection of serious adverse events (SAEs)  X To be reported at any time during the 
study  
Collection of pregnancies  X To be reported at any time during the 
study  
End of Active Phase participation record  X  X  
*  The investigator or an authorized designee will interview the participant to collect the information recorded in the DC and w ill 
attempt to clarify anything that is incomplete or unclear.  
†  To comply with US FDA expectations, Sponsors are to enroll participants who reflect the demographics for clinically relevant populations with regard to age, gender, race and ethnicity as described in 
https://www.fda.gov/downloads/regulatoryinformations/guidances/ucml126396.pdf. 
‡  In female participants of childbearing potential (ie, not post -menopausal for at least 1 year, or surgically sterile). 
§  Physical examination based on medical history will be performed at Visit 1. Targeted physical examination may also be 
performed at Visit 2, as necessary.  
**  Participants will use this diary card to record information about solicited reactions from D01 to D08, as well as unsolicited AEs, SAEs, and AESIs until Visit 2. 
††  Staff will collect the diary card at Visit 2, and review any solicited reactions ongoing at Visit 2, Unsolicited AEs, concomitant 
medication, SAEs and AESIs.  
‡‡  During this call the staff will review the memory aid with the participant and determine whether the participant experienced any SAE or AESI not yet reported.  
CRF: case report form   
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 13 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28780] disease caused by 
[CONTACT_29488],  in population, from infants to 
elderly . Compared to the licensed vaccines Prevnar  13 and Pneumovax 23, SP0202 investigational 
vaccine contains 21 serotypes:13 serotypes common to those of Prevnar 13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and 8 additional serotypes ( 8, 9N, 10, 11A, 12F, 15B, 22F, 33F) ; 
the later are  common to Pneumovax 23. These 21 serotypes are conjugated to 2 different protein 
carriers, either tetanus toxoid (TTxd) or cross -reacting material 197, a non-toxic mutant of 
diphtheria toxin (CRM
197). These two protein carriers included in the PCV21 formulation have 
proven safety records. The long-term benefit of unconjugated vaccines in elderly population was recently discussed as their protection -induced is weak and short lived because of the absence of B -
cell memory production following immunization (2)  (3). Therefore , the conjugation technology 
using a carrier protein to polysaccharides has been used to increase immunogenicity in elderly population. Protein carrier specific  T-cells provide the signal needed for maturation of the B- cell 
response and generation of B-cell memory, and production of high affinity antibodies.  
Four formulations of SP0202 investigational vaccine (with different content of serotypes and 
different serotypes conjugated to either TTxd or CRM
197) were evaluated in Phase I study 
PSK000007. They differed by [CONTACT_29496] (2 or 4) and by [CONTACT_29497]13. ( Table  2.2).  
Table  2.1: Specifi cities of the [ADDRESS_28781] been developed (see Table  6.1 for their composition). All 3 formulations will include 4 serotypes 
conjugated to TTxd (serotypes 1, 5, 15B and 22F). It is to be noted that the TTxd content will be decreased compared to  SP0202-II formulation tested in the Phase I study following changes in the 
manufacturing process of serotypes 15B and 22F (increased polysaccharide / tetanus toxoid ratio, expected to improve immune response). 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 14 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 15 of 69 With regards to the antigen content per serotypes: 
• Formulation IIb will include  µg for all serotypes but 6B (  µg) 
• Formulation VI will differentiate from IIb with serotypes 3, 19A and 19F at  µg  
• Formulation VII will differentiate from IIb with serotypes 3, 4, 9V, 19A and 19F at  µg  
The SP0202 investigational vaccine is designed for immunization of infants/toddlers and elderly 
against pneumococcal disease. Phase II study PSK00008 including toddlers aged 12- 15 months, 
and infants aged 42 to 89 days will be conducted in parallel with the current Phase II study 
PSK00009 including healthy adults aged 50 to 84 years. 
2.2 Background 
S. pneumoniae  (or pneumococcus) is a Gram -positive diplococcus, encapsulated with a diverse 
range of polysaccharides. Based on the differences in the polysaccharide capsule, [ADDRESS_28782] been described  (4) (5) (6). The most common disease -causing 
serotypes observed throughout the world are generally similar. However, there may be large variations in the relative serotype prevalence in these regions,  particularly between developed and 
developi[INVESTIGATOR_14696] (7) . 
The microorganism, through the asymptomatic colonization of the nasopharynx, is a major cause of several infections, including pneumonia, meningitis, bacteremia, sinus and otitis media (6) . 
Infections characterized by [CONTACT_29498] S. pneumoniae  from a normal sterile site, such as 
blood, cerebrospi[INVESTIGATOR_872], or synovial fluid, identified as occurrences of invasive pneumococcal disease (IPD).  
In order to offer protect ion against S. pneumoniae  infections, vaccines against serotype specific 
capsular polysaccharides have been developed. The first pneumococcal polysaccharide vaccines (PPSV) were brought to the market in [ADDRESS_28783] 14- valent vaccine was licensed and in 
1983 the vaccine coverage was expanded to 23 S. pneumoniae  serotypes (8) . In the following 
years, 23-valent PPSVs were shown to reduce the risk of IPD in adults (9), although protection 
against pneumococcal pneumonia has not yet been convincingly demonstrated (10) (11). In 
addition, PPSVs have shown a poor immunogenicity in children aged less than 2 years (ie, the 
most vulnerable age group to pneumococcal infections), an inability to generate immune memory 
at any age, and no effect on pneumococcal carriage (12)  (13)  (14). 
As a way to offer a stronger and longer-lasting protection to populations in which PPSVs are the least immunogenic (ie, children under 2 years, adults over 65 years, and immunocompromised persons), second generation pneumococcal vaccines have been developed by [CONTACT_29499] S. pneumoniae  capsular  polysaccharides with carrier proteins to induce both humoral and cellular 
immune response (12) . Pneumococcal conjugate vaccines (PCVs) have been shown to be effective 
in preventing pneumococcal pneumonia, IPD, and otitis in children (15)  (16) (17)  (18) (19)  (20). 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 15 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 16 of 69 Ever since the introduction of a 7-valent PCV in 2000a, the overall number of IPD cases, 
especially the number of cases due to serotypes covered by [CONTACT_29500], has been declining (13)  
(14). Strengthening this trend, the introduction of a 10- valent PCV (2009)b and a 13- valent PCV 
(2010)c has confirmed the indirect benefit generated by [CONTACT_29501] (ie, herd immunity in unvaccinated population) and in ant imicrobial resistance (13)  (21)  
(22). PCVs have had an important impact on public health in developed countries, as well as 
worldwide; since global roll out (9). 
However, it is now acknowledged that serotypes covered by [CONTACT_29502] (21)  (23)  (24) . Less fit or emergent serotypes simply 
take advantage of an ecological niche left vacant (25). One of most notable examples is serotype 
19A which emerged as a predominant serotype in several countries with no PCV7 vaccination 
programs (7) . 
Currently, few strategies aiming to mitigate this phenomenon of serotype replacement are being 
developed. One possible solution would be to design a vaccine that combines 2 classes of complementary antigens, one to prevent colonization (ie, pneumococcal polysaccharides) and another to limit virulence transition (ie, protein antigens that selectively target pneumococci virulence transition) (26). The proof of concept of such an approach has not been demonstrated to 
date. Another possible solution is to introduce a PCV that includes a higher number of serotypes to cover the emerging ones and hence to protect against a higher number of pneumococcal strains causing invasive disease.  
[COMPANY_011] Pasteur  has decided to move forwards with the latter approach, a next generation of PCV 
comprising 21 serotypes (PCV21). Such a vaccine candidate has the potential to address important medical and public health needs by [CONTACT_29503].  
2.3 Benefit/Risk Assessment 
More det ailed information about the known and expected benefits and risks, reasonably expected 
adverse events, the potential risks, and uncertainties of SP0202 may be found in the Investigator’s Brochure (IB) . 
                                                 
a Prevnar®. Pneumococcal 7 -valent Conjugate vaccine (Diphtheria CRM 197 Protein), [COMPANY_007] Inc.  
b Synflorix®. Pneumococcal conjugate vaccine (Non- typeable Haemophilus influenzae [NTHi] protein D, diphtheria 
or tetanus toxoid conjugates) absorbed, GlaxoSmithKline Biological S.A.  
c Prevnar  13®. Pneumococcal 13 -valent Conjugate Vaccine (Diphtheria CRM 197 protein), [COMPANY_007] Inc.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 16 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 17 of 69 2.3.1 Risks from Study Participation  
The potential risks of clinical significance and risk management are summarized in  Table  2.2 
Table  2.2: Potential risks of clinical significance and risk management 
Potential Risk of Clinical 
Significance  Summary of Data/Rationale 
for Risk  Risk Management  
Investigated Vaccine: SP0202  
• Anaphylaxis 
• Guillain-Barré Syndrome  
• Arthus -type hypersensitivity 
• Gastrointestinal disorders 
(vomiting)  
• Headache  
• Myalgia, arthralgia  
Refer to IB Section [ADDRESS_28784] the potential to cause allergic reactions or anaphylaxis in individuals who 
may be sensitized to components of the vaccine. 
Refer to the IB Section 5 and 
Section 6  for more information 
regarding the data from previous 
experience with the investigated vaccine. Exclusion criteria 8 and 9 for 
those at increased risk.  
Observation period after 
vaccination for early detection and treatment.  
Comparator: Prevnar 13  
Refer to the package insert for 
more information regarding 
potential risks . Identified and potential risks 
observed in clinical trials and/or 
post-marketing surveillance. Exclusion/inclusion criteria take 
in account contraindications, 
warnings and precautions as defined in product label.  
Comparator: Pneumovax 23  
Refer to the package insert for more information regarding potential risks. Identified and potential risks observed in clinical trials and/or post-marketing surveillance. Exclusion/inclusion criteria take in account contraindications, warnings and precautions as defined in product label.  
Study Procedures  
Vasovagal reactions (syncope), or psychogenic reactions  to 
needle (vaccine injection or blood sampling).  Anxiety -related reactions can 
occur following, or even  before, 
any vaccination as a psychogenic response to the needle injection 
or blood draw, and may be 
accompanied by [CONTACT_29504], paresthesia or seizure-like activity.  Observation period after vaccination for early detection 
and treatment.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 17 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 18 of 69 2.3.2 Benefits from Study Participation  
Four formulations of SP0202 investigational vaccine were evaluated in Phase I clinical study 
(PSK00007) that was carried out in healthy adults aged [ADDRESS_28785] pneumococcal disease 
due to 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). 
Participants who will receive Pneumovax [ADDRESS_28786] pneumococcal 
disease due to 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 23F, and 33F). 
As with any vaccines, SP0202 formulations and Prevnar 13, and Pneumovax 23, vaccines 
administered during the study may not protect 100% of individuals against the disease they are designed to prevent.  
2.3.[ADDRESS_28787] Covid -19. However, the risk of exposure to infected people cannot be completely 
excluded as the participants may need to expose to public area (eg, commute to the site and at the 
site).  
2.3.4 Overall Benefit -Risk Conclusion  
Considering the measures taken to minimize risk to participants enrolled in this study, the  
potential risks that may result from study participation are balanced by [CONTACT_29505]. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 18 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 19 of 69 3 Objectives and Endpoints  
Table  3.1: Objectives and endpoints  
Objectives  Endpoints  
Immunogenicity  
To assess the immune response of the 3 
SP0202 formulations, Prevnar  13, and 
Pneumovax 23, 30 days after the 
administration of the single dose 
vaccination  • Serotype -specific OPA titers for all pneumococcal 
serotypes included in the SP0202 formulations, as 
determined by [CONTACT_29490] (MOPA), at baseline (D01)  and 30 days after 
vaccination  (D31)  
• Serotype -specific OPA titers ratio (post/pre -injection)  
for all pneumococcal serotypes included in the SP0202 formulations as determined by [CONTACT_29491] 
• Serotype -specific IgG concentrations for all 
pneumococcal serotypes included in the SP0202 formulations as measured by [CONTACT_29492] -chemiluminescence assay (ECL), at baseline 
(D01) and 30 days after vaccination  (D31)  
• Serotype -specific IgG concentration ratios 
(post/pre -injection) for all pneumococcal serotypes 
included in the SP0202 formulations as measured by 
[CONTACT_29506] 3 SP0202 formulations, Prevnar  13, and 
Pneumovax 23 • Presence of any unsolicited systemic AEs reported in 
the 30 minutes after injection of a SP0202 formulation, Prevnar  13, or Pneumovax 23  
• Presence of solicited (ie, pre -listed in the participant’s 
DC and in the CRF ) injection site reactions occurring 
up to 7 days a fter the day of injection  (D08) of a 
SP0202 formulation, Prevnar 13, or Pneumovax 23 
• Presence of solicited (ie, pre -listed in the participant’s 
DC and in the CRF ) systemic reactions occurring up to 
7 days after the day of injection  (D08) of a SP0202 
formul ation, Prevnar 13, or Pneumovax 23  
• Presence of unsolicited (spontaneously reported) AEs 
up to 30 days after the day of injection (D31) of a 
SP0202 formulation, Prevnar 13, or Pneumovax 23 
• Presence of SAEs and AESIs, throughout the study 
period (up to 6-mon th follow -up) 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 19 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 20 of 69 4 Study Design  
4.1 Overall Design 
The design of the study is summarized in Table  4.1. 
Table  4.1: Overall design  
Type of design  Parallel, multi center  
Phase  II 
Control method  Active -controlled  
(controls = Prevnar  13 and Pneumovax  23) 
Study population  Healthy adults aged 50 to 84 years  
Level and method of blinding  Modified double -blind  (observer -blind)  
Study intervention assignment method Randomization with stratification by [CONTACT_29507]  750 participants , approximately 150 in each group  
(approximately 375 aged 50 to 64 years and 37 5 aged 65 
to 84 years)  
Intervention groups  In each site and age group , randomization in a 1:1:1:1:1 
ratio to receive a single injection of either 1 of the 3 
formulations of SP0202, Prevnar  13, or Pneumovax  23 
Total duration of study participation  Approximately 6 months  
Countries  [LOCATION_002] of America  
Use of an Independent Data Monitoring 
Committee, Dose Escalation Committee, or 
similar review gr oup Yes 
4.2 Scientific Rationale for Study Design  
PSK00009 is a Phase II study that will evaluate the immunogenicity and safety of 3 SP0202 
formulations administered as a single dose to healthy adults aged 50 to 84 years naïve to prior pneumococcal vaccine administration . Two groups will serve as controls and receive a single dose 
of either Prevnar 13 or Pneumovax 23.  
In the US, pneumococcal vaccination with Prevnar  13 (a 13-valent conjugated vaccine) or 
Pneumovax 23 (a 23-valent unconjugated vaccine) is recommended by [CONTACT_29508] (27) : 
• Pneumovax 23: for all immunocompetent adults ≥ 65 years old (yo), for people 19 to 64 yo 
with certain conditions and for adults 19 to 64 yo who smoke cigarettes. 
• Prevnar 13: in adults with certain medical conditions, for immunocompetent adults ≥ [ADDRESS_28788] not previously received Prevnar 13 based on shared clinical decision -making. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 20 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 21 of 69 In this study, Prevnar 13 will serve as a reference vaccine for safety assessment and for 
immunogenicity of the 13 common serotypes with SP0202. Pneumovax 23 will provide a reference for the immune response to the 8 additional serotypes in SP0202 formulations. 
Given the acceptable safety data generated in PSK00007 study (Phase I study), no early safety 
data review is planned for this study. The safety will be continuously monitored by [CONTACT_1034]. 
The safety data collected will be entered into the CRF and summarized by [CONTACT_1034]. Blinded 
review s will be performed by [CONTACT_29509] (SMT) meetings. 
An unblinded review by a Data Monitoring Committee (DMC) will also be conducted to assess the safety data, including AESIs, SAEs and safety profile of each SP0202 formulation when at least [ADDRESS_28789] safety data up to D31 (30 days after 
injection ) available. The DMC will also review the unblinded safety data collected on all 
participants up  to D31. 
Due to differences in the appearance of SP0202, Prevnar 13, and Pneumovax [ADDRESS_28790] an observer- blinded design (double -blind across SP0202 formulations) to limit 
any bias in the assessment of safety. The designated vaccine preparer(s)/administrator(s) will be 
unblinded given the different aspect of the products, but neither the participant nor the investigator nor the study staff in charge of vaccination will know which vaccine will be administered. The 
unblinded designated vaccine preparer(s) /administrator(s) will not be involved in any of the 
blinded study assessments (eg, immunogenicity, safety). The Investigators (or delegate) in charge 
of safety assessment, the study staff who collect the safety data, and the laboratory personnel who 
analyze the blood samples will not know which product was administered. 
Note : at this stage  and based on currently available information, this is not known whether prior 
history of exposure to SARS -CoV-2 (2019- nCoV)  would impact the immune response to 
pneumococcal vaccines. 2019-nCoV serology screening prior to vaccination is not included. 
However, serum samples could be tested to determine participants’ sero-status regarding 2019-
nCOV at the time of the study  if deemed necessary according to the available scientific 
knowledge. This assessment may be done during immunogenicity assessment or at any time . 
4.[ADDRESS_28791] procedure recommended by [CONTACT_29510]  (1). 
The antigen content for each serotypes is simil ar to Prevnar 13, except for serotypes 3, 19A and 
19F in formulation SP0202 VI and serotypes 3, 4, 9V, 19A, and 19F in formulation VII. 
4.[ADDRESS_28792] completed the study if he/she has completed the last phone c all 
planned in the SoA. 
The end of the study is defined as the date of the last  visit of the last participant in the study. 
However, for periodic safety reports, the study is considered completed when the clinical study 
report is finalized.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 21 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 22 of 69 5 Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 Inclusion Criteria  
Participants are eligible for the study only if all of the following criteria are met:  
I01: Aged 50 to 84 years on the day of inclusiona. 
I02: Informed consent has been signed and dated. 
I03: Able to attend all scheduled visits and to comply with all trial procedures. 
5.2 Exclusion Criteria  
Participants are not eligible for the study if any of the following criteria are met: 
E01: Participant  is pregnant, or lactating, or of childbearing potential and not using an 
effective method of contraception or abstinence from at least [ADDRESS_28793] 1 year, or surgically sterile.  
E02: Participation at the time of the study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the pre sent trial period in another clinical 
trial investigating a vaccine, drug, medical device or medical procedure  
E03: Receipt of any vaccine in the [ADDRESS_28794] 2 weeks before study vaccine. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.  
E04: Previous vaccination against S. pneumoniae  with either a pneumococcal conjugated 
vaccine (PCV) or a pneumococcal polysaccharide vaccine (PPSV).  
E05: Receipt of immune globulins, blood or blood-derived products in the past 3 months. 
E06: Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long- term systemic corticosteroid therapy 
(prednisone or equivalent for more than [ADDRESS_28795] 3 months). 
                                                 
a “50 to 84 years” means from the day of the 50th  birthday to the day before the 85th  birthday 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 22 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 23 of 69 E07: History of S. pneumoniae  infection or disease, confirmed either serologically, or 
microbiologically. 
E08: History of Guillain -Barré syndrome occurring within 6 weeks after a prior dose of a 
TTxd -containing vaccine. 
E09: Experienced an Arthus- type hypersensitivity reaction follo wing a prior dose of a 
TTxd -containing vaccine < 10 years ago. 
E10: Known systemic hypersensitivity to any of the vaccine components, or history of a 
life-threatening reaction to the vaccines used in the trial or to a vaccine containing any 
of the same substancesa. 
E11: Verbal report of thrombocytopenia contraindicating IM vaccination in the Investigator’s opi[INVESTIGATOR_1649] 
E12: Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination in the Investigator’s opi[INVESTIGATOR_1649]. 
E13: At risk of invasive pneumococcal disease (eg , participant with functional or anatomic 
asplenia, participants  with severe asthma, participants  travelling to countries with high 
endemicity).  
E14: Deprived of freedom by [CONTACT_29511], or in an emergency setting, or hospi[INVESTIGATOR_29476]. 
E15: Current alcohol abuse or drug addiction. 
E16: Chronic illness that, in the opi[INVESTIGATOR_689], is at a stage where it might interfere with trial conduct or completion
b. 
E17: Any condition that in the opi[INVESTIGATOR_29477] (eg, under investigation or monitoring for possible coronavirus disease 2019 [COVID-19]) 
E18: Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4°F). A prospective participant should not be included in the study until the condition has resolved or until 3 days after the febrile event has subsided.  
E19: Receipt of oral or injectable antibiotic therapy within [ADDRESS_28796] blood draw.  
                                                 
a The component of the SP0202 formulations are listed in Section  6.1 and in the Investigator’s Brochure. The 
components of Prevnar  13 and Pneumovax 23 are listed in Section  6.1 and in their prescribing information. 
b Participants with pre -existing stable chronic condition, determined based on medical history and clinical judgement 
of the investigator are eligible.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 23 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 24 of 69 E20: Identified as an Investigator or employee of the Investigator or study center with direct 
involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of t he Investigator or employee with direct 
involvement in the proposed study. 
If the participant has a primary physician who is not the Investigator, the site should contact [CONTACT_29512]’s consent to inform him / her of the participant’s participation in the study. In addition, the site should ask this primary physician to verify exclusion criteria relating to previous therapi[INVESTIGATOR_014], such as receipt of blood products or previous vaccines. 
5.3 Lifestyle Considerations  
No other restrictions than the ones listed in the exclusion criteria or in the contraindications for subsequent vaccinations are required. 
5.4 Screen Failures  
Screen failures are defined as participants who are contact[CONTACT_29513] (eg, inclusion and/or exclusion criteria) . 
Screening information is recorded in the source documents.  
Individuals who do not meet the criteria for participation in this study (screen failure)  cannot be 
rescreened.  
6 Study Intervention  
Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study 
protocol. 
Note: routine vaccine administered outside of study protocol are not considered as study 
interventions. 
6.1 Study Intervention(s) Administered 
Study interventions are described in  Table  6.1. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 24 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
Confi
dential/Proprietary Information  
Page 25 of 69 Table  6.1: Identity of study intervention(s)  
Group Name  [CONTACT_26374] 1  
SP0202-IIb  Group 2  
SP0202-VI  Group 3  
SP0202-VII  Group 4  
Prevnar  13 Group 5  
Pneumovax 23 
Intervention 
Name  [CONTACT_29561] 13-valentConjugateVaccinePneumoc occal 
Vaccine Polyvalent  
Use Experim ental  Experimental  Experimental  Active 
comparator  Active comparator  
IMP and NIMP  IMP IMP IMP IMP IMP 
Type Vaccine  Vaccine  Vaccine  Vaccine  Vaccine  
Dose 
Formulation Suspension for injection 
in a pre -filled 
syringe  Suspension for 
injection in a 
pre-filled 
syringe  Suspension for injection in a 
pre-filled 
syringe  Suspension for injection in a 
pre-filled 
syringe  Solution for injection in a 
pre-filled  
syringe  
Unit Dose  
Strength(s)   µg of 
polysaccharid
e from S. pneumonia
e serotypes 3,
4, 6A, 7F, 8,
9N, 9V, 10A,11A, 12F, 14,18C, 19A,
19F, 23F,
33F, and µg ofpolysaccharide for serotype
6B;
individuallyconjugated toCRM
197
protein
 
µg of
polysaccharide frompneumococcal serotypes 1,5, 15B and
22F
individuallyconjugated to
TTxd carrierprotein µg of 
polysaccharide from S. pneumoniae
serotypes 4,
6A, 7F, 8, 9N,9V, 10A, 11A,12F, 14, 18C,23F, 33F, and
 µg of
polysaccharidefor serotypes3, 6B, 19A,and 19F;
individually
conjugated toCRM
197
protein
 
µg of
polysaccharide
from
pneumococcalserotypes 1, 5,15B, and 22Findividually
conjugated to
TTxd carrierprotein µg of 
polysaccharide from S. pneumoniae
serotypes 6A,
7F, 8, 9N,10A, 11A,12F, 14, 18C,23F, 33F, and
 µg of
polysaccharidefor serotypes3, 4, 6B, 9V,19A, and 19F;
individually
conjugated toCRM
197
protein
 
µg of
polysaccharide
from
pneumococcalserotypes 1, 5,15B, and 22F;individually
conjugated to
TTxd Carrierprotein2.2 µg of polysaccharide from S. pneumoniae
serotypes 1, 3,
4, 5, 6A, 7F,9V, 14, 18C,19A, 19F, 23Fand 4.4 µg of
polysaccharide
for serotype6B;individuallyconjugated to
CRM
197
protein25 
µg of 
polysaccharide 
from S. pneumoniae
serotypes 1, 2,
3, 4, 5, 6B, 7F,8, 9N, 9V,10A, 11A, 12F,14, 15B,  17F,
18C, 19A, 19F,20, 22F, 23Fand 33F
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 25 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 26 of 69 Excipi[INVESTIGATOR_840] / 
Diluent  Succinic acid, NaCl, Polysorbate  80
, aluminum (0.125 mg) 
and water for 
injection  NaCl, Phenol and water for injection  
Dosage Level  0.5 mL per dose  
Number of doses / Dosing Interval  1 dose  
Route of Administration IM injection  
Site of Administration Deltoid muscle in the upper arm  
Injection Site Side On the arm opposite to blood sample 
Sourcing  Provided by [CONTACT_29514]. All will be labeled as 
required per country requirement.  
Current/Former Name(s) or Alias(es)  Not applicable Not applicable Not applicable Prevnar  13® Pneumovax®23 
Batch Number  TBD TBD TBD TBD TBD 
IMP: Investigational Medicinal Product; NIMP: Non- Investigational Medicinal Product; CRM 197: Cross -Reacting 
material 197; TBD: To be determined  
6.2 Preparation/Handling/Storage/Accountability  
Detailed guidance and information are provided in the Operating Guidelines. 
1) The investigator or designee must conf irm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention. 
2) Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage condition s with access limited to the investigator and 
authorized site staff.  
3) The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance ( ie, 
receipt, reconciliation, and final disposition records). 
4) Further guidance and information for the final disposition of unused study interventions are provided in the Operating Guidelines. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 26 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 27 of 69 5) Prior to administration, all study products must be inspected visually for cracks, broken seals, 
correct label content, and extraneous particulate matter and / or discoloration, whenever solution or container permit. If one of these conditions exists, the vaccine must not be administered, a replacement dose is to be used, and the event is to be reported to the Sponsor. 
6) Since some study intervention are a suspension containing an adjuvant, it has to be shaken vigorously prior use to obtain a homogenous suspension. Do not use the study intervention if it cannot be resuspended . 
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.1 Randomization and Allocation Procedures  
This study will be a randomized, modified double-blind study for 5 vaccine groups. 
On the day of enrollment, participant who meet the inclusion/exclusion criteria and sign the 
informed consent form (ICF) will be randomly assigned to Groups 1 through 5 in a 1:1:1:1:[ADDRESS_28797] approximately 150 
participants ( around 75 participants aged 50 to 64 years and around 75 participants aged 65 to 84 
years).  
The unblinded vaccinator  or delegate will connect to the IRT, enter the identification and security 
information, and confirm a minimal amount of data in response to IRT prompts. The IRT will then provide the group assignment and have the site staff confirm it. The full detailed procedures for group allocation are described in the Operating Guidelines. If the participant is not eligible to participate in the study, then the information will only be recorded on the participant recruitment log. 
Participant numbers that are assigned by [CONTACT_29515] a 12 -digit string (a 3 -digit country 
identifier, a  4-digit study center identifier, and a 5- digit participant identifier). The first digit of the 
participant identifier will be “1” for participants aged 50 to 64 years and “2” for participants aged 
65 to 84 years. For example, Participant 840000210005 is t he fifth participant aged 50 to 64 years 
enrolled in Center Number 2 in the US (840 being the US code country). 
Participant  numbers should not be reassigned for any reason. The randomization codes will be 
kept securely in  the IRT and an internal system.  
6.3.2 Blinding and Code -breaking Procedures  
The study will be performed in a modified double-blind fashion: 
• The unblinded qualified trial staff member, independent of the immunogenicity and safety 
evaluations and other trial evaluations will administer the study intervention. 
• The Investigators (or delegates) in charge of safety assessment, the trial staff who collect the 
safety data, and the laboratory personnel who analyze the blood samples will be blinded and 
not know which product was administered. 
• The participant will not know which product was administered.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 27 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 28 of 69 • Only the study staff who prepare and administer the vaccine and are not involved with the 
safety evaluation will know which vaccine is administered  
The Investigator responsible for safety assessment  will not attend the vaccination session but will 
be available in case of emergency (anaphylactic shock).  
Treatment numbers will be used to identify each vaccine syringe for the purpose of randomization, vaccination and the recording of the study intervent ion administered. Treatment 
numbers will be randomly assigned to study interventions syringes. The IRT vendor will be responsible for assigning the treatment group identification and treatment number to be received by [CONTACT_29516]. The participant, the Investigator, and the study staff members who collect the safety data and laboratory personnel who analyze the blood samples will all be blinded to the group assignment. The individual responsible for preparing / administering study intervention w ill not be authorized to collect any safety / serology data. 
The code may be broken in the event of an AE only when the identification of the vaccine received could influence the treatment of the participant. Code-breaking should be limited to the 
particip ant(s) experiencing the AE. 
The blind can be broken by [CONTACT_29517] a delegate through the IRT system, as explained in the code-breaking procedures described in the Operating Guidelines. Once the emergency has been addressed by [CONTACT_779], the Investi gator or a delegate must notify the [COMPANY_011] Pasteur 
Responsible Medical Officer ( RMO) if a participant’s code was broken. All contact [CONTACT_29518], and the code-breaking case repo rt form (CRF)  is to be completed. 
The I ndependent Ethics Committees (IEC)  / Institutional Review Boards (IRB) must be notified 
of the code-breaking, in accordance with local regulations . All documentation pertaining to the 
event must be retained in the sit e’s study records and in the [COMPANY_011] Pasteur files. Any intentional 
or unintentional code-breaking must be reported, documented, and explained, and the name [CONTACT_29562]. 
A request for the code to be broken may also be made:  
• by [CONTACT_29519] (GPV) Department through an internal system for 
reporting to Health A uthorities in the case of an unexpected SAE considered causally 
related as described in International Council for Harmonization ( ICH) E2A . In this case, 
the code will be broken only for the participant (s) in question. The information resulting 
from code- breaking ( ie, the participant’s vaccine or group assignment) will not be 
communicated to either the Investigator or the immediate team work ing on the study, 
except for the GPV representative.  
A first statistical analysis of the safety and immunogenicity data obtained up to 30 days after 
vaccination (V02) will be conducted once data are available and an interim database l ock has been 
conducted. The blind of participants will be broken for the analysis, but the randomization list will 
not be provided to Investigators until completion of the 6-month safety follow-up and will be kept internally. A final analysis will be conducted once the 6 -month safety data has been collected and 
the final database lock has occurred . If the V01-V02 immunogenicity data release is planned at 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 28 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28798]  safety data up to D31 (30 days after injection ) available . The DMC will 
also conduct another unblinded review of the safety data collected on all participants up to D31. 
An unblinded external independent statistician will share the unblinded safety data with the DMC 
members. The information will not be communicated to either the Investigator or the Sponsor study team before the end of the trial and database lock. 
If during the internal SMT /DMC review  a further in -depth review of the data and partial or full 
unblinding is required by [CONTACT_1034], it will be done by [CONTACT_29520]. 
The code-breaking procedures are described in the Operating Guidelines and in the DMC charter.  
6.4 Study Intervention Compliance  
The following measures will ensure that the study intervention is  administered as planned (see 
Table  6.1), and that any noncompliance is documented so that it can be accounted for in the data 
analyses:  
• All vaccinations will be administered by [CONTACT_29521] 
• The person in charge of study intervention management at the site will maintain 
accountability records of study intervention delivery to the study site, study intervention 
inventory at the site, dose given to each participant, and unused or wasted doses 
6.5 Concomitant Therapy  
At the time of enrollment, ongoing medications and other therapi[INVESTIGATOR_014] (eg, blood products) should be 
recorded in the source documenta as well  as new medications prescribed for new medical 
conditions / AEs during study participation. 
Documentati on in the CRF  of ongoing concomitant medication(s) will be limited to specific 
categories of medication(s) of interest beginning on the day of first vaccination. This may include 
medications of interest that were started prior to the day of vaccination.  
Reportable medications will be collected in the CRF  from the day of vaccination (D01)  to the end 
of the solicited and unsolicited follow-up period (D31 + 14 days). 
Reportable medications include medications that impact or may impact  the consistency of the safety 
information collected after any vaccination and/or the immune response to vaccination. Three standard 
categories of reportable medications are defined:  
                                                 
a Participant  will be required to document in the DC all medications received.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 29 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 30 of 69 • Category 1:  medications impacting or that may have an impact on the evaluation of the 
safety ( eg, antipyretics, analgesics, and non- steroidal anti -inflammatory drugs [NSAIDs], 
systemic steroids/corticosteroids  [therapy duration for less than 2 consecutive weeks]) 
• Category 2:  medications impacting or that may have an impact on t he immune response  
(eg, other vaccines [including influenza vaccine in the 2 weeks [14 days] preceding or 
following any IM  vaccination], blood products, antibiotic classes taken within 3 day [72 
hours] prior to blood draw that may interfere with bioassays used by [CONTACT_29522] [GCI] department or other testing laboratories , immune -suppressors, 
immune -modulators with immunosuppressive properties, anti- proliferative drugs such as 
DNA synthesis inhibitors, immune  globulins in the 3 months preceding vaccination ) 
• Category 3:  medications impacting or that may have an impact on both the safety and the 
immune response (eg, long- term systemic corticosteroids  therapy [prednisone or 
equivalent for more than 2 consecutive weeks]) 
The information reported in the CRF  for each reported medication will be limited to:  
• Trade name [INVESTIGATOR_8178] a medication composed of several molecules OR international nonproprietary 
name (INN) for a medication composed of one single molecule 
• Origin of prescription: prophylaxis Yes/No. Medication(s) prescribed for AE prophylaxisa will 
be recorded in the Action Taken of the AE collection tables. 
• Medication category (1, 2, or 3) 
• Start and stop dates  
Dosage and administration route, homeopathic medication, topi[INVESTIGATOR_8826]  (inhaled, otic, 
ophthalmic, nasal etc.) treatments will not be recorded. Topi[INVESTIGATOR_29478]; however, if they are applied inadvertently to the vaccination site, they should be recorded as a Category 1 medication in this specific instance.  
Medications given in response to an AE will be captured in the “Action Taken” section of the AE CRF only. No details will be recorded in the concomitant medication CRF unless  the medication(s) 
received belongs to one of the pre- listed  categories. Medications will not be coded . 
6.5.1 Rescue Medicine  
Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
6.6 Dose Modification  
Not applicable. 
                                                 
a Medication(s) prescribed for preventing AE occurrence (eg , paracetamol to reduce the risk of fever).  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 30 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 31 of 69 7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
7.1 Discontinuation of Study Intervention  
7.1.1 Temporary contraindications 
The following is a temporary contraindication to blood draw BL0002 at Visit 2: 
1) Receipt of oral or injectable antibiotic therapy within 72 hours prior to blood draw. 
Note: If a participant receives oral or injectable antibiotic therapy within [ADDRESS_28799] still be within the timeframe for blood draw. If postponement would result in the sample collection falling outside this timeframe, the blood sample should be collected without postponement, and it should be documented appropriately (in source document and CRF ) that the  sample was taken less than 
3 days after stoppi[INVESTIGATOR_29479]. 
7.2 Participant Discontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons. This is expected to be uncommon. 
• The reason for withdrawal should be clearly documented in the source documents and in the CRF : Adverse Event, Lost to Follow-up, Protocol Deviation, or Withdrawal by 
[CONTACT_3445].  
• The participant will be permanently discontinued both from the study intervention and from the study at that time.  
• If the participant withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws consent, he/she may request destruct ion of any samples taken 
and not tested, and the investigator must document this in the site study records. 
• Withdrawn participants will not be replaced.  
Follow- up of Discontinuations  
For participants who have prematurely terminated the study, the site should attempt to contact 
[CONTACT_29523]-ups, except if they specified that they do not want to be contact[CONTACT_29524]. 
For participants where the reason for early termination  is lost to follow -up, the site will not 
attempt to obtain further safety information. See  Section  7.3 for definition of “lost to follow-up”. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 31 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28800] be taken if a participant fails to return to the site f or a required study 
visit or cannot be contact[CONTACT_29525]: 
• The site must attempt to contact [CONTACT_29526]/or should continue in 
the study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods), or at least to determine his/her health status while fully respecting 
his/her rights. These contact [CONTACT_13140]’s medical 
record. 
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 10.1. 
8 Study Assessments and Procedures  
• Study procedures and their timing are summarized in the SoA. Protocol waivers or exemptions are not allowed. 
• Immediate safety concerns should be discussed wit h the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study intervention. 
• Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.  
Blood samples will be collected as described in the S oA table (Section  1.3). 
The maximum amount of blood collected from each participant over the duration of the study, 
including any extra assessments that may be required, will not exceed 40 mL. Repeat or 
unschedule d samples may be taken for safety reasons or for technical issues with the samples.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 32 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 33 of 69 Guidance and information for the sample collection, preparation, storage, and shipment are 
provided in the Operating Guidelines. 
8.1 Efficacy and Immunogenicity Assessments 
8.1.1 Efficacy Assessments  
No clinical efficacy data will be obtained in the study. 
8.1.2 Immunogenicity Assessments  
Multiplexed opsonophagocytic killing assay (MOPA) 
This method will be performed on BL0001 and BL0002 collected on D01 and D31 respectively.  
Assays will be performed by [CONTACT_3642] (a CRO laboratory), Richmond (VA), [LOCATION_003]. 
Pneumococcal capsular polysaccharide – electro -chemiluminescent assay (PnPS- ECL)  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 33 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 34 of 69 This m
ethod will be performed on BL0001 and BL0002 collected on D01 and D31 respectively. 
Assays will be performed by [CONTACT_29527] (GCI), Swiftwater (PA), 
[LOCATION_003].  
8.2 Safety Assessments  
This section pre sents safety assessments other than adverse events which are presented in  
Section  8.3. 
Planned time points for all safety assessments are provided in the SoA ( Section  1.3). 
8.2.[ADDRESS_28801] and ongoing. Any such conditions will be documented in the source document. Significant (clinically relevant) medical history (reported as diagnosis) including conditions/illnesses for which the participant is or has been followed by a physician or conditions/illnesses that could resume during the course of the study or lead to an SAE or to a repetitive outpatient care will be collected in the CRF . 
8.2.2 Physical Examinations  
At Visit 1 , the Investigator or a delegate will perform a physical examination based on medical 
history and including evaluat ion of the following body systems: general appearance, skin, head, 
eyes, ears, nose, throat, heart, lungs abdomen, musculoskeletal, extremities, neurological and lymph nodes examination. A targeted physical examination may also be performed at Visit 2, as necessary.  Information will be recorded in the source document. 
Temperature measurement will be done  during the physical examination before vaccination and 
recorded in the source document. 
8.2.[ADDRESS_28802] not be used. 
8.2.4 Clinical Safety Laboratory Assessments  
Urine pregnancy testing will be performed in women of childbearing potential before vaccination.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 34 of 70

[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 35 of 69 8.3 Adverse Events and Serious Adverse Events  
The definitions of an AE, SAE , and the different categories of AEs can be found in 
Appendix 10.3. 
AEs will  be reported by [CONTACT_29528], then by [CONTACT_29529]. The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain  responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that caused the participant to discontinue the study (see Section  7). 
8.3.[ADDRESS_28803]-vaccination observation should be documented in the source document and immediate events will be recorded at D01 in the eCRF.  
Reactogenicity  
Solicited injection site reactions will be collected from D 01 to  D08 after vaccination.  
Solicited systemic reactions will be collected from D 01 to D08 after vaccination.  
The solicited injection site reactions and systemic reactions that are pre -listed  in the diary cards 
and CRF , together with the intensity scales, are presented in Appendix [IP_ADDRESS].1. 
Unsolicited Non -serious Adverse Events  
Unsolicited non- serious adverse events will be collected from D 01 to D31 after vaccination.  
The intensity grading scale for unsolicited non- serious adverse events is presented in 
Appendix [IP_ADDRESS].2. 
Adverse Events of Special Interest  (AESIs)  
AESIs will be collected throughout the study period, from D01 unt il [ADDRESS_28804] of AESIs.  
SAEs  
Information on SAEs will be collected and assessed throughout the study, from D01  until 6 
months after vaccination.  
Medical occurrences that begin before the start of study intervention but after obtaining informed 
consent will not be recorded on the AE section of the CRF. 
All SAEs will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 10.3. The investigator will submit any updated SAE data to the Sponsor within 24 hours of it being available. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 35 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 36 of 69 Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation . However, if the investigator learns of any SAE, including a death, at any time after a 
participant h as been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the investigator must promptly notify the 
Sponsor. 
8.3.[ADDRESS_28805] be captured in the source document and then reported electronically.  
The 6 -month follow-up will be done by [CONTACT_29530] a 
questionnaire to capture SAEs and AESIs, if applicable.  
The method of recording, evaluating, and assessing causal relationship  of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Appendix 10.3. 
Care will be taken not to introduce bias when detectin g AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrences.  
8.3.[ADDRESS_28806], each participant who experiences an AE (whether 
serious or non-serious) during the study must be followed until the condition resolves, becomes stable, or becomes chronic (even after the end of the participant’s participation in the study) if either  of the following is true: 
• The AE is considered by [CONTACT_29531]  
• The AE caused the discontinuation of the participant from the study or from vaccination 
The Investigator will inform the Sponsor of the date of final disappearance of the event or the date 
of “chronicity” establishment.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 36 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 37 of 69 8.3.4 Regulatory Reporting Requirements for SAEs 
• Prompt notification by [CONTACT_29532] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country- specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB/I EC, and investigators. 
• For all studies except those investigating medical devices investigator safety reports must 
be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local regulatory requirements and Sponsor policy and forwarded to investigators as 
necessary.  
• An investigator who receives an investigator safety report describing a SAE or other 
specific safety information ( eg, summary or listing of SAEs) from the Sponsor will 
review and then file it and will notify the IRB/IEC, if appropriate according to local 
requirements.  
8.3.5 Pregnancy  
Pregnancy is an exclusion criterion for enrollment in this study, but a participant could potentially 
become pregnant during her participation. 
• Details of all pregnancies in female participants will be collected after the start of study intervention and until delivery by [CONTACT_29533]. Any data collected after CR F lock will be transmitted to the pharmacovigilance 
department on the paper form. 
• If a pregnancy is reported, the investigator should inform the Sponsor within 1 month of 
learning of the pregnancy and should follow the procedures outlined in Appendix 10.4. 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
8.3.[ADDRESS_28807] be done. AESI wi ll be collected throughout the study . AESI include the 
following: 
• Anaphylaxis defined as per the Brighton collaboration case definition (28) . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 37 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 38 of 69 8.4 Treatment of Overdose  
Since the study intervention is administered by a health care professional, it is unlikely that 
overdose by [CONTACT_29534]. 
However, in the event of an overdose, the Investigator should:  
1) Contact [CONTACT_27465].  
2) Closely monitor the participant for any AE/SAE.  
3) Docume nt the quantity of the excess of the overdose in the source documents. 
8.5 Pharmacokinetics  
Pharmacokinetics parameters are not evaluated in this study.  
8.6 Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study.  
8.7 Genetics 
Genetics are not evaluated in this study. 
8.8 Biomarkers  
No other biomarkers than those described in the immunogenicity assessments section 
(Section  8.1.2) are evaluated in this study. 
8.9 Immunogenicity Assessments 
See Section  8.1.2. 
8.10 Medical Resource Utilization and Health Economics  
Medical Resource Utilization and Health Economics parameters are not evaluated in this study.  
9 Statistical Considerations  
9.1 Statistical Hypothes es 
No hypotheses will be tested. The analyses will be descriptive.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 38 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 39 of 69 9.2 Sample Size Determination  
There are no statistically powered hypotheses in this study thus no formal sample size 
computation. The number of participants  is judged sufficient to provide useful immunogenicity 
and safety data on the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23. 
The sample size was set to approximatively 150 participants  per vaccine group and 
approximatively 75 by [CONTACT_551]. Assuming a drop-out rate of approximatively 15%, a total of 
128 participants  by [CONTACT_29299] (P er Protocol Analysis Set [PPAS]) are expected.  
The expected precision of estimation for quantitative data is as follows (PPAS)  - the maximum 
distance from the log10 mean to the limits of 95% CI is equal to 0.173 for single mean and 0.246 
for difference in means of two groups (when the standard deviation is 1). 
 
Standard 
deviation  N evaluable  Distance between 
log 10 mean and 
95%CI limits for 
a single mean  Distance between 2 
groups difference in 
log 10 means and 
95%CI limits  Distance between 
GMT and 
95%CI limits for 
a single mean  Distance from 
GMT ratio 
between 2 groups 
to 95%CI upper 
limit  
0.5 128 0.087  0.123  1.22 1.33 
0.6 128 0.104  0.148  1.27 1.41 
0.7 128 0.121  0.172     1.32 1.49 
0.8 128 0.139  0.197     1.38 1.57 
0.9 128 0.156  0.222     1.43 1.67 
1 128 0.173  0.246     1.49 1.76 
9.3 Populations for Analyses  
The following populations are defined: 
Population  Description  
Randomized  All participants  with data in the CRF 
Safety Analysis Set  (SafAS) Participants who have received the study vaccine. All participants will 
have their safety analyzed  according to the vaccine they actually 
received.  
Safety data recorded for a vaccine received out of the protocol design will be excluded from the analysis (and listed separately).  
Full analysis set (FAS)  Subset of randomized participants who received at least [ADDRESS_28808] -vaccination blood sample result.  
Participants will be analyzed according to the intervention to which they 
were randomized.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 39 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 40 of 69 Per-protocol analysis set 
(PPAS) Subset of the FAS. Participants presenting with at least one of the 
following relevant protocol deviations will be excluded from the PPAS:  
• Participant did not meet all protocol-specified inclusion criteria or met at least one of the protocol -specified exclusion criteria  
• Participant did not receive vaccine  
• Participant received a vaccine other than the one that he / she was 
randomized to recei ve 
• Preparation and / or administration of vaccine was not done as per -
protocol  
• Participant did not provide the post -dose serology sample at V2 in 
the proper time window or a post -dose serology sample was not 
drawn  
• Participant received a protocol-prohibited therapy / medication / 
vaccine) 
In addition to the reasons listed above, participants will also be excluded from the PPAS if their Visit 02 / post -vaccination serology 
sample did not produce a valid test result ( ie, results for all antigens are 
missing).  
In the event of a local or national immunization program with a pandemic influenza vaccine, participants who receive 1 or more doses of a pandemic influenza vaccine at any time during the study will not be withdrawn from the study.  
9.4 Statistical Analyses  
The statistical analysis plan (SAP) will be finalized prior to database lock and it will include a 
more technical and detailed description of the statistical analyses described in this section. This 
section is a summary of the planned statistical analyses of the most important endpoints. 
9.4.1 General Considerations 
All analyses will be descriptive.  
For immunogenicity data, assuming that log10 transformation of the titers / concentrations and titers / concentrations ratio follows a normal distribution, first, the  mean and 95% confidence 
intervals (CIs) will be calculated on log10 (titers / concentrations; titers / concentrations ratio) using the usual calculation for normal distribution, then antilog transformations will be applied to the results of calculations, to compute geometric mean titers / concentrations (GMTs / GMCs) and geometric mean of the individual titer / concentration ratios (GMTRs / GMCRs) and their 
95% CIs.  
The 95% CIs of ratio of GMTs / GMCs between 2 groups will be computed from the difference o f 
log 10 transformed means of titers/concentrations using normal approximation. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 40 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 41 of 69 The 95% CIs of point estimates will be calculated using the exact binomial distribution 
(Clopper-Pearson method (29) ) for proportions. 
Generally, no replacement of missing data will be done. 
9.4.2 Safety Analyses 
Safety analyses will be performed on the SafAS and presented by [CONTACT_29535] (main endpoints). The main parameters will be described with 95% CI. At least 
number and percentages of participants will be presented  after vaccine i njection reporting any: 
• Immediate unsolicited systemic AEs 
• Solicited injection site reactions and solicited systemic reactions occurring within 7 days after the day of injection (D1 to D8) according to presence, time of onset, intensity (Grade 1, Grade 2, or Grade 3), number of days of presence and action taken 
• Unsolicited AEs occurring within 30 days after injection by [CONTACT_9313] (SOC) and 
preferred term ( PT), relationship, intensity, time of onset, and duration 
• All SAEs occurring throughout the study by [CONTACT_3592], relationship and seriousness criteria 
• All AESIs occurring throughout the study by [CONTACT_29536]. Nevertheless, missing relationship will be 
considered as related at the time of statistical analysis.  
9.4.3 Immunogenicity Analyses 
All immunogenicity analyses will be performed on the PPAS and presented by [CONTACT_29537]. Additional immunogenicity analyses will be performed on the FAS. 
The point estimates and their 95% CI of at least the following parameters will be presented before 
and 1-month post- vaccination for each pneumococcal serotype specific OPA titers and IgG 
concentrations:  
• GMT/GMC of serotype specific titers/concentrations 
• GM of titers/ concentrations ratio (post- / pre -vaccination)  
Differences in terms of ratio of GMTs/GMCs between 2 groups (ie, any SP0202 formulations and 
Prevnar 13 or Pneumovax 23) post- vaccination will be presented.  
Reverse cumulative distribution curves (RCDCs) of individual concentrations/titers will be 
presented for all serotypes at pre and post -vaccination. 
Missing data will not be imputed. No test or search for outliers will be performed.  
For the calculation of GMTs / GMCs and percentage above cut -offs, any pre-vaccination or 
post-vaccination value reported as < LLOQ will be converted to a value of 0.5 LLOQ. 
For the calculation of GMTR / GMCR, any pre- vaccination value reported as < LLOQ will be 
converted to LLOQ, and any post-vaccination value reported as < LLOQ will be converted to a 
titer of 0.5 LLOQ when only either the numerator or the denominator is < LLOQ. If both 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 41 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 42 of 69 numerator and denominator are < LLOQ, then both will be converted in the same way so that the 
increase is defined as 1.  
Any value reported as > ULOQ (upper limit of quantitation) will be converted to ULOQ. 
9.4.4 Other Analyses  
Any further analyses will be described in the SAP. 
9.5 Interim Analyses  
This study will not include an early safety data review. However, participant safety will be 
continuously monitored by [CONTACT_1034]’s internal safety r eview committee (SMT)  which includes 
safety signal detection at any time during the study. The analyse s for SMT will be blinded and 
descriptive therefore  no statistical adjustment is necessary . 
A DMC will review continuously related AESIs and related SAEs up the 6-month follow-up. In 
addition, a first DMC safety analysis on data  collected on at least 150 participants up to D31 
(30 days after injection ) will be conducted in an unblinded manner  by [CONTACT_29538]’t be communicated to the Sponsor. The DMC will also review the 
unblinded safety data collected up to D31 on all participants. The analyses for this scope will be 
descriptive so no statistical adjustment is necessary.  
A statistical analysis of the safety and immunogenicity objectives up to V02 ( Day 31) will be 
conducted once data on all participants  are available and an interim database lock has been 
conducted. The blind will be broken for the analysis and kept at the S ponsor level until the 6-
month follow-up completion. No statistical adjustment is necessary because no hypotheses will be tested. A final analysis will be conducted once the 6-month safety data has  been collected and the 
final database lock has occurred.  
If the  V01 -V02 immunogenicity data release is planned at the time or after the 6 -month safety  
data availability, only one database lock and one analysis including all data may be conducted. 
The SAP  will describe the planned analyses in greater detail.  
9.6 Data  Monitoring Committee (DMC) 
A DMC has been implemented to oversee the safety data of the SP0202 clinical program and will 
be utilized throughout this study. The committee will assess the safety data in an unblinded manner. This includes the related AESIs a nd related SAEs review on ongoing basis, as well as 
safety profile of each SP0202 formulation prior to database lock. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 42 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 43 of 69 10 Supporting Documentation and Operational Considerations  
10.1 Appendix: Regulatory, Ethical, and Study Oversight Considerations  
Note: The term “ participant” is used throughout this protocol. However, the term “subject” will be 
used in the CRF  in order to comply with the Clinical Data Interchange Standards Consortium 
(CDISC) requirements.  
10.1.1 Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations (eg, data protection law as General Data Protection 
Regulation [GDPR]) 
• The protocol, protocol amendments, ICF , IB, and other relevant documents (eg, 
advertisements) must be submitted to an IRB/IEC by [CONTACT_29539] 
(according to local regulations) and reviewed and approved by [CONTACT_1201]/IEC before the study is initiated  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants 
• The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC  
• Determining whether an incidental finding (as per [COMPANY_011] policy) should be returned to a participant and, if it meets the appropriate  criteria, to ensure the finding is returned (an 
incidental finding is a previously undiagnosed medical condition that is discovered unintentionally and is unrelated to the aims of the study for which the tests are being performed). The following should be considered when determining the return of an incidental finding: 
• The return of such information to the study participant (and/or his/her designated healthcare professional, if so designated by [CONTACT_2299]) is consistent with all applicable national, state, or regional laws and regulations in the country where the study is being conducted, and 
• The finding reveals a substantial risk of a serious health condition or has 
reproductive importance, AND has analytical validity, AND has clinical validity.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 43 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 44 of 69 • The p articipant in a clinical study has the right to opt out of being notified by [CONTACT_21481]. In the event that the participant has opted 
out of being notified and the finding has consequences for other individuals, eg, the finding relates to a communicable disease, Investigators should seek independent 
ethical advice before determining next steps.  
• In case the participant has decided to opt out, the Investigator must record in the site medical files that she/he does not want to know about such findings. 
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.1.2 Financial Disclosure  
Information related to financial disclosure is described in the Investigator’s contract.  
10.1.3 Informed Consent Process  
• The invest igator or his/her representative will explain the nature of the study to the participant 
or his/her legally authorized representative and answer all questions regarding the study.  
• Participants must be informed that their participation is voluntary. Participants will be required 
to sign a statement of informed consent that meets the requirements of [ADDRESS_28809] (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also s ign the ICF.  
• The actual ICF used at each center may differ, depending on local regulations and IEC / IRB requirements. However, all versions must contain the standard information found in the sample ICF provided by [CONTACT_1034]. Any change to the content of the ICF must be approved by [CONTACT_29540] / IRB prior to the form being used. 
• If new information becomes available that may be relevant to the participant’s willingness to continue participation in the study, this will be communicated to him / her in a timely manner. 
Such information will be provided via a revised ICF or an addendum to the original ICF. 
• Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s legally authorized 
representative.  
The ICF will contain a specific section that addresses the use of remaining mandatory samples for optional exploratory research. The investigator or authorized designee will explain to each 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 44 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28810] an appropriate pool 
of potential participant s and invite them to participate in the study. The site will ensure that any 
advertisements used to recruit participan ts (eg, letters, pa mphlets, posters) are submitted to [COMPANY_011] 
Pasteur prior to submission to the IEC / IRB for approval. 
10.1.4 Data Protection and Future Use of Stored Samples  
• All personal data collected related to participants, Investigators, or any person involved in the 
study, which may be included in the Sponsor’s databases, shall be treated in compliance with 
all applicable laws and regulations including the GDPR. Data collected must be adequate, relevant and not excessive, in relation to the purposes for which they are collected. Each category of data must be properly justified and in line with the study objective. 
• Participants race and ethnicity will be collected in this study because these data are required by [CONTACT_17513] (eg, on African- American po pulation for the Food and Drug 
Administration).  
• Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information which would make the participant identifiable will not be transferred to the Sponsor. 
• The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be explained to the participant as described in the informed consent. 
• The participant must be informed that his/her medical records may be examined by [CONTACT_9325], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
• When archiving or processing personal data pertaining to the Investigator and/or to the participants, the Sponsor shall take all appropriate measures to safeguard and prevent ac cess to 
this data by [CONTACT_13159]. 
• Participant data will be used for this study and in support of the whole drug development 
program for the Investigational Product, including negotiations with payers and publication of 
results.  
• Any unused part of the serum samples will be securely stored by [CONTACT_29541]  [ADDRESS_28811]’s licensure and the potential revalidation of the study results.  
The other biological samples collected to qualify the participant for inclusion in the study or to monitor his/her health are dedicated for immediate use. In case they are not completely used 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 45 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28812] at the end of the study or after the time requested by 
[CONTACT_1769].  
In addition, participants  will be asked to indicate in the ICF whether they will permit the 
future use of any unused stored serum samples for other tests. If they refuse permission, the samples will not be used for any testing other than that directly related to this study. If they agree to this use, they will not be paid for giving permission. Anonymity of samples will be ensured. The aim of any possible future research is unknown today, and may not be related to this particular study. It may be to improve the knowledge of vaccine s or infectious diseases, or 
to improve existing tests or develop new tests to assess vaccines. Human genetic tests will never be performed on these samples without specific individual informed consent. 
10.1.5 Committees Structure  
This study will not include an e arly safety data review. However, participant safety will be 
continuously monitored by [CONTACT_1034]. A blinded review will be performed by [CONTACT_29509]  (SMT)  meeting which includes safety signal detection at any 
time during the study. Two  unblinded reviews by a Data Monitoring Committee (DMC) will also 
be conducted. 
10.1.6 Dissemination of Clinical Study Data  
[COMPANY_011] shares information about clinical trials and results on publicly  accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other 
clinical trial disclosure commitments established by [CONTACT_13174].   These 
websites include clinicaltrials.gov, EU clinical trial  register (eu.ctr), and sanofi.com, a s well as 
some national registries.  
In addition, results from clinical trials in patients are required to be submitted to peer- reviewed 
journals following internal company review for accuracy, fair balance, and intellectual property. For those journals tha t request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to submit their request to clinicalstudydatarequest.com.  
Individual participant data and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of participants in our clinical trials. Details on data sharing criteria and process for requesting access can be found at this web address: cli nicalstudydatarequest.com. 
10.1.7 Data Quality Assurance 
• All participant data relating to the study will be recorded on electronic CRF  unless transmitted  
to the Sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_29542] . 
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 46 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 47 of 69 • The investigator must permit study -related m onitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
• Monitoring details describing strategy (eg, risk -based initiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), 
methods, responsibilities and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) are provided in the Monitoring 
Plan.  
• The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (eg, Contract 
Research Organizations).  
• Study monitors will perform ongoing source data verification to confirm that data entered into the CRF  by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] 25 years after the signature [CONTACT_29563] a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
10.1.8 Source Documents  
“Source data” are the data contained in source documents. Source documents are original 
documents or certified copi[INVESTIGATOR_014], and include, but are not limited to, diary cards, medical and 
hospi[INVESTIGATOR_1097], screening logs, informed consent / assent forms, telephone contact [CONTACT_29543], and worksheets.  
• Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
• Data entered in the CRF  that are transcribed  from source documents must be consistent with 
the source documents or the discrepancies must be explained. The investigator may need to 
request previous medical records or transfer records, depending on the study. Also, current medical records must be available.  
Detailed guidance and information are provided in the Operating Guidelines. 
10.1.[ADDRESS_28813] 
participant.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 47 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28814] been completed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is g iven in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_29544]:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by [CONTACT_093] 
• Discontinuation of further study intervention development 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow- up. 
10.1.10 Publication Policy  
Information related to publication policy is described in the Investigator’s contract.  
10.2 Appendix: Clinical Laboratory Tests  
A urine human chorionic gonadotropin (hCG) pregnancy test (as needed for women of childbearing potential)
 will be performed before vaccination. 
10.3 Appendix: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 48 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 49 of 69 10.3.1 Definition of A E 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered related to the study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments ( eg, ECG, radiological scans, vital signs measurements), including those 
that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator ( ie, not related to progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase 
in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study intervention administration even though it 
may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae.  
 
Events NOT Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by [CONTACT_19448]’s condition. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipate d day- to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
 
Other Definitions  
Adverse Reaction:  
All noxious and unintended responses to a study intervention related to any dose should be considered adverse reactions (AR).  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 49 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 50 of 69 (The phrase “responses to a study intervention” means that a causal relationship between a 
study intervention and an AE is at least a reasonable possibility)  
Immediate Event/Reaction:  
Immedi ate events are recorded to capture medically relevant unsolicited systemic AEs 
(including those related to the study intervention administered) that occur within the first 30 
minutes after vaccination.  
Injection Site Reaction:  
An injection site reaction is  an AR at and around the injection site. Injection site reactions are 
commonly inflammatory reactions. They are considered to be related to the study intervention  
administered . 
Systemic AE /AR: 
Systemic AEs are all AEs that are not injection or administration site reactions. They therefore 
include systemic manifestations such as headache, fever, as well as localized or topi[INVESTIGATOR_29480] (eg, erythema 
that is localized but that is not occurring at the injection site).  
Systemic AEs assessed as related to study intervention are referred as systemic ARs.  
Adverse Event of Special Interest (AESI):  
An adverse event of special interest (serious or non -serious) is one of scientific an d medical 
concern specific to the Sponsor’s study intervention or program, for which ongoing monitoring and rapid communication by [CONTACT_29545]. Such an event might warrant further investigation in order to characteriz e and understand it. Depending on the 
nature of the event, rapid communication by [CONTACT_29546] (eg, regulators) 
might also be warranted.  
Reactogenicity / Solicited Reactions
 
A solicited reaction is an “expected” adverse reaction (sign  or symptom) observed and reported 
under the conditions (nature and onset) pre- listed  in the protocol and CRF  (eg, injection  site 
pain or headache occurring between the day of vaccination and the next 7 days ). 
By [CONTACT_108], solicited reactions are considered as being related to the study intervention 
administered.  
For injectable vaccines, solicited reactions can either be solicited injection site reactions or 
solicited systemic reactions.  
Unsolicited AE /AR 
An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions, 
ie, pre- listed  in the CRF  in terms of diagnosis and/or onset window post- vaccination. For 
example, varicella or a solicited term such as headache starting after the solicited observation 
period (headache starting on Day [ADDRESS_28815]-vaccination in the case where headache occurring 
between the day of vaccination and the next 7 days is pre-listed in the protocol and CRF as a solicited reaction).  
An unsolicited AR  is an  unsolicited AE that is considered related to study intervention. 
Unsolicited AEs includes both serious (SAEs) and non- serious unsolicited AEs.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 50 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 51 of 69 10.3.2 Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life- threatening  
The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_19949] (usually involving at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. Whe n in doubt as to 
whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache,  nausea, vomiting, diarrhea, influenza, and 
accidental trauma ( eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Other important medical event  
• Medical or scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations such as important medical events that may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_29481]. These important medical events should also usually be 
considered serious. 
• Examples of such events are intensive treatm ent in an emergency room or at home for 
allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], 
or development of drug dependency or drug abuse, new-onset diabetes or autoimmune 
disease.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 51 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 52 of 69 Note:  Serious and severe are not synonymous. The term severe is often used to describe the 
intensity of a specific event as corresponding to Grade 3. This is not the same as serious,  which is 
based on participant / event outcome or action criteria usually associated with events that pose a 
threat to a participant’s life or functioning.  
10.3.3 Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF . 
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s me dical 
records to the Sponsor in lieu of completion of the CRF  pages.  
• There may be instances when copi[INVESTIGATOR_29482]. In this case, all participant identifiers, with the exception of the participant numb er, will be redacted on the copi[INVESTIGATOR_19361]. 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
 
Assessment of Causal Relationship 
By [CONTACT_559], all AEs reported at the injection site (whether solicited or unsolicited) and all 
solicited systemic AEs are considered to be related to the study intervention (see definition in 
Section  6 and therefore are referred to as reactions and do not require the Investigator’s opi[INVESTIGATOR_29483]. 
• Causal relationship  of unsolicited systemic AEs and SAEs will be recorded as follows: 
• For non- serious unsolicited systemic AEs (except for non -serious AESIs), relationship 
to study intervention will usually be assessed by [CONTACT_29547].  
• For SAEs and non- serious AESIs, relationship to study intervention will be assessed 
by [CONTACT_29548]. Sponsor assessment is entered in the GPV 
database only.  
• For SAEs only, the causal relationship to study procedures (related/not related to study 
procedures) will be assessed by [CONTACT_29548]. Sponsor 
assessment is entered in the GPV database only.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 52 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 53 of 69 • The Investigator will assess the causal relationship  between each unsolicited systemic AE 
and the study intervention administereda as either not related  or related , based on the 
following definitions: 
• Not rela ted – The AE is clearly / most probably caused by [CONTACT_29549], therapeutic intervention, or concomitant therapy; or the delay 
between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE started before the vaccination  
• Related – There is a “reasonable possibility” that the AE was caused by [CONTACT_29550], meaning that there is evidence or arguments to suggest a causal relationship  
• The investigator will use clinical judgment to determine the relationship. 
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.  
• The investigator will also consult the IB and/or Product Information, for marketed products, 
in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an a ssessment of causal relationship . 
• There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important that the investigator always make an assessment of causal relationship  for every event before the 
initial transmission of the SAE data to the Sponsor.  
• The investigator may change his/her opi[INVESTIGATOR_29484]-up 
information and send a SAE follow-up report with the updated causal relationship  
assessment.  
• The causal relationship  assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow- up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by [CONTACT_29551]/ or causal relationship  of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
                                                 
a Study intervention  administered can correspond to either the investigational product or other products when no 
investigational product is administered a t the visit 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 53 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 54 of 69 • If a participant dies during participation in the study or during a recognized follow-up 
period, when available the investigator will provide the Sponsor with a copy of any post-mortem findings including histopathology. 
• New or updated information will be recorded in the originally completed CRF . 
• The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information.  
• Adverse events likel y to be related to the study intervention , whether serious or not, that 
persist at the end of the study will be followed up by [CONTACT_29552] ’s condition. The Investigator will 
inform the Sponsor of the date of final disappearance of the event or the date of “chronicity” 
establishment.  
10.3.4 Reporting of SAEs  
SAE Reporting to the Sponsor via an Electronic Data Collection Tool 
• The primary mechanism for reporting an SAE to the Sponsor will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection tool (see next section) in order to report the event within 24 hours. The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data. 
• If a site receives a report of a new SAE fr om a study participant or receives updated data on 
a previously reported SAE after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE form (see next section).  
• Details regarding SAE reportin g can be found in the Operating Guidelines.  
 
SAE Reporting to the Sponsor via Paper CRF 
• The SAE paper CRF can be sent to the Sponsor by [CONTACT_29553]: 
• By [CONTACT_6791], to the following number: [PHONE_425] 
• In PDF format to the following e-mail address, using a method of transmission that includes password protection: [EMAIL_453] 
• By [CONTACT_29554], to the following address:  
[COMPANY_011] Pasteur Inc.  
Reception and Triage – Case Management  
Global Pharmacovigilance 
Mail Drop: 45D38, Discovery Drive 
Swiftwater, PA [ZIP_CODE]  
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 54 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 55 of 69 Safety Emergency Call 
If, as per the Investigator's judgment, a participant experiences a medical emergency, the 
Investigator may contact [CONTACT_1034]'s RMO for advice on how to address any study- related 
medical question or problem. If the RMO is not available, then the Investigator may contact [CONTACT_29555] —available 24  hours a day, 7 days a week —that will forward all safety emergency 
calls to the appropriate primary or back -up [COMPANY_011] Pasteur contact, as needed. The toll -free 
contact [CONTACT_29556]. 
This process does not replace the need to report an SAE. The Investigator is still required to 
follow the protocol-defined pr ocess for reporting SAEs to the GPV Department.  
In case of emergency code-breaking, the Investigator is required to follow the code-breaking 
procedures described in Section  6.3.2 . 
10.3.5 Assessment of Intensity  
The investigator will make an assessment of intensity for each AE reported during the study. An intensity grade will be assigned to each AE. The intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007”.  
[IP_ADDRESS] Tables for Clinical Abnormalities  
[IP_ADDRESS].1 Solicited AR Intensity Grading Scale  
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 55 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 56 of 69 Table  10.1: Solicited injection site reactions: terminology, definitions, and intensity scales  
CRF  term 
(MedDRA lowest 
level term [LLT])  Injection site pain  Injection site erythema  Injection site swelling  
Diary card term  Pain Redness  Swelling  
Definition Pain either present spontaneously or when 
the injection site is touched or injected limb is mobilized
 Presence of a redness including the approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a fluid infiltration in tissue or cavity and, depending on the space available for the fluid to disperse, swelling may be either soft 
(typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to touch and 
thus can be best described by [CONTACT_29557]/Proprietary Information 
                 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 56 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 57 of 69 Intensity scale*  CRF : 
Grade 1: A type of adverse event that is 
usually transient and may require only 
minimal treatment or therapeutic 
intervention. The event does not generally 
interfere with  usual activities of daily living.  
Grade 2: A type of adverse event that is 
usually alleviated with additional 
therapeutic intervention. The event 
interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 
Grade 3: A type of adverse event that 
interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade 1: No interference wit h usual 
activities  
Grade 2: Some interference with usual 
activities  
Grade 3: Significant; prevents usual 
activities  Grade 1: ≥ 25 to ≤  50 mm 
Grade 2: ≥ 51 to ≤  100 mm 
Grade 3: > 100 mm Grade 1: ≥ 25 to ≤  50 mm 
Grade 2: ≥ 51 to ≤  100 mm 
Grade 3: > 100 mm 
MedDRA: Medical Dictionary for Regulatory Activities  
* For the subjective reaction of pain, participants  will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness and swelling, they will 
record just the size of the reaction, and the classification as Grade 1, 2, or 3 will be assigned at the time of the statistical analysis  
  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 57 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 58 of 69 Table  10.2: Solicited systemic reactions: terminology, definitions, and intensity scales  
CRF  term 
(MedDRA 
lowest level term [LLT])  Fever  Headache  Malaise  Myalgia  Arthralgia  Shivering  
Diary card term  Temperature  Headache  Feeling unwell  Muscle aches and pains  Joint pain  Chills  
Definition Elevation of temperature to ≥°38.0°C (≥  100.4°F)  Pain or discomfort in the head or scalp. Does not include migraine.  General ill feeling.  
Malaise is a generalized feeling of 
discomfort, illness, or 
lack of well -being 
that can be associated with a disease state. It can be accompanied by a sensation of 
exhaustion or 
inadequate energy to 
accomplish usual activities.  Muscle aches and pains are common and can involve more than one muscle at the same time. Muscle 
pain can also involve 
the soft tissues that surround muscles. These structures, which are often referred to as 
connective tissues, include ligaments, tendons, and fascia (thick bands of tendons).  
Does not apply to muscle pain at the injection site which should be reported as injection site pain.  Pain in a joint or joints  Sensation of cold 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 58 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 59 of 69 Intensity 
scale*  Grade 1: ≥ 38.0°C to 
≤ 38.4°C,  
or ≥ 100.4°F to 
≤ 101.1°F  CRF : 
Grade 1: A type of 
adverse event that is usually transient and may require only minimal treatment or 
therapeutic 
intervention. The event does not generally interfere with usual activities  
of daily living.  CRF : 
Grade 1: A type of 
adverse event that is usually transient and may require only minimal treatment or 
therapeutic 
intervention. The event does not generally interfere with usual activities of daily living.  CRF : 
Grade 1: A type of 
adve rse event that is 
usually transient and may require only minimal treatment or 
therapeutic 
intervention. The event does not generally interfere with usual activities of daily living.  CRF : 
Grade 1: A type of 
adverse event that is usually transient and 
may require only 
minimal treatment or 
therapeutic intervention. The event does not 
generally interfere 
with usual activities of daily living.  CRF : 
Grade 1: A type of 
adverse event that is usually transient and 
may require only 
minimal treatment or therapeutic intervention. The event does not 
generally interfere 
with usual activities of daily living.  
 Grade 2: ≥ 38.5°C to 
≤ 38.9°C,  
or ≥ 101.2°F to 
≤ 102.0°F  Grade 2: A type of 
adverse event that is usually alleviated 
with additional 
therapeutic intervention. The  
event interferes with usual activities of 
daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. Grade 2: A type of 
adverse event that is usually alleviated 
with additional 
therapeutic intervention. The event interferes with usual activities of 
daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. Grade 2: A type of 
adverse event that is usually alleviated 
with additional 
therapeutic interve ntion. The 
event interferes with usual activities of 
daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. Grade 2: A type of 
adverse event that is usually alleviated 
with additional 
therapeutic intervention. The 
event interferes with usual activities of 
daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. Grade 2: A type of 
adverse event that is usually alleviated 
with additional 
therapeutic intervention. The event interferes with usual activities of 
daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 59 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 60 of 69  Grade 3: ≥ 39.0°C  
or ≥ 102.1°F  Grade 3: A type of 
adverse event that 
interrupts usual activities of daily 
living, or significantly 
affects clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade 1: No 
interference with usual activities  
Grade 2: Some 
interference with usual activities  
Grade 3: Significant; 
prevents usual activities  Grade 3: A type of 
adverse event that interrupts usual activities of daily 
living, or significantly 
affects clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade 1: No 
interference with  
usual activities  
Grade 2: Some 
interference with usual activities  
Grade 3: Significant; 
prevents usual activities  Grade 3: A type of 
adverse event that interrupts usual activities of daily 
living, or significantly 
affects clinical status, or may require intensive therapeutic 
intervention.  
Diary card:  
Grade 1: No 
interference with usual activities  
Grade 2: Some 
interference with usual activities  
Grade 3: Significant; 
prevents usual activities  Grade 3: A type of 
adverse event that interrupts usual activities  of daily 
living, or significantly affects clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade 1: No 
interference with usual activities  
Grade 2: Some 
interference with usual activities  
Grade 3: Significant; 
prevents usual activities  Grade 3: A type of 
adverse event that interrupts usual activities of daily 
living, or significantly 
affects clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade 1: No 
interference with usual activities  
Grade 2: Some 
interference with usual activities  
Grade 3: Significant; 
prevents usual activities  
MedDRA: Medical Dictionary for Regulatory Activities  
* For all reactions but fever,  participants will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body temperature, and the classification as 
Grade  1, 2, or 3 will be assigned at the time of the statistical analysis based on the unit used to measure the temperature and the  intensity scale.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 60 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 61 of 69 Important notes for the accurate assessment of temperature:  
Participants are to measure body temperature once per day, preferably always at the same time. 
The optimal time for measurement is the evening, when body tem perature is the highest. 
Temperature is also to be measured at the time of any apparent fever. The observed daily temperature and the route of measurement are to be recorded in the diary card , and the highest 
temperature will be recorded by [CONTACT_29558] . The preferred route for this study is axillary.  
[IP_ADDRESS].[ADDRESS_28816] of solicited reactions, the corresponding scale for solicited reactions will be used (see Section  [IP_ADDRESS].1).  
All other unsolicited AEs will be classified according to the following intensity scale:  
• Grade 1  
• CRF : A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.  
• Diary card: No interference with usual activities.  
• Grade 2  
• CRF : A type of adverse event that is  usually alleviated with additional therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 
• Diary card: Some interference wi th usual activities.  
• Grade 3  
• CRF : A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention.  
• Diary card: Significant; prevents usual activities.  
10.4 Appendix: Collection of Pregnancy Information  
DEFINITIONS:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below).  
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP  
1) Premenarchal  
2) Premenopausal fem ale with 1 of the following: 
• Documented hysterectomy  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 61 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 62 of 69 • Documented bilateral salpi[INVESTIGATOR_1656] 
• Documented bilateral oophorectomy 
 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview.  
3) Postmenopausal female 
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required. 
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
COLLECTION OF PREGNANCY INFORMATION  
Female Participants who become pregnant  
• The investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. The initial information together with the contraceptive method if any will be recorded on the appropriate form and submitted to the Sponsor within 1 month of learning of a participant's pregnancy. 
• The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follo w-up information on the participant and the neonate and the information will 
be forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery date, but will be in accordance with local regulations. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termina tion of a pregnancy for medical reasons will be reported as an AE or SAE. 
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at 
>22 weeks gestational age) is always considered to be an SAE and will be reported as such . 
• Any post-study pregnancy related SAE considered reasonably related to the study intervention by [CONTACT_29559]  8.3.4. While the 
investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 62 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 63 of 69 • In case of pregnancy during the primary series and if at least 1 dose of the study vaccine(s) has 
been administered, the participant will not be discontinued from the study, but no further 
vaccination will be administered until after delivery (if applicable and still within the study vaccination window). However , the participant will be followed for safety assessment (and 
may be followed for immunogenicity assessment, if applicable). 
10.5 Appendix: Risk -based Approach  
ICH E6 -R2 guideline for GCP is introducing the « risk-based approach » concept which permits 
to focus efforts on what is critical for a study and most specifically on Critical Data and Critical Processes. Critical data and processes are defined for the study with associated risks in the Study 
Risk Management Plan.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 63 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 64 of 69 10.6 Appendix: Abbreviations  
AE  Adverse Even ts 
AESI   Adverse events of special interest  
AR  Adverse reactions  
CRF   Case report form  
DMC   Data Monitoring Committee  
FAS  Full analysis set  
FSH  Follicle stimulating hormone 
GCI  Global Clinical Immunology 
GCP   Good Clinical Practice  
GDPR   General Data Protection Regulation  
GPV   Global Pharmacovigilance 
HRT   Hormonal replacement therapy 
IB  Investigator’s Brochure 
ICF  informed consent form 
ICH  International Council for Harmoniz ation  
IEC  Independent Ethics Committees 
IgG  immunoglobulin G 
IMP  Investigational Medicinal Product  
IPD  invasive pneumococcal disease  
IRB  Institutional Review Boards  
IRT  Interactive Response Technology  
MedDRA  Medical Dictionary for Regulatory Activities  
MOPA   multiplex opsonophagocytic assay 
NIMP   Non- Investigational Medicinal Product;  
PCV   pneumococcal conjugate vaccine  
PPAS   Per-protocol analysis set 
PPSV   pneumococcal polysaccharide vaccine 
PT  preferred term  
RMO   Responsible Medical Officer  
SAE   Serious adverse events  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 64 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 65 of 69 SafAS   Safety Analysis Set  
SAP  Statistical ana lysis plan  
SOC   system organ class  
SMT  Safety Management Team  
SoA  Schedule of Activities 
TBD   to be determined 
WHO   World Health Organization 
WOCBP  Woman of Childbearing Potential 
yo  year old 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 65 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 66 of 69 10.7 Appendix: Protocol Amendment History  
The Protocol Amendment Rationale for the current amendment is located directly before the 
Table of Contents. 
 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 66 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 67 of 69 11 References 
1. CDC. Pneumococcal Vaccination: Summary of Who and When to Vaccinate  [Available 
from: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who- when -to-vaccinate.html . 
2. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-
specific effectiveness of [ADDRESS_28817] pneumococcal 
pneumonia in adults aged 65 years or older: a multicentre, prospective, test- negative design study. 
Lancet Infect Dis. 2017;17(3):313- 21. 
3. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen -
specific B cells. J Infect Dis. 2012;205(9):1408 -16. 
4. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015;28(3):871-99. 
5. Klugman KP, Black S, Dagan R, Malley R, Whitney CG. Pneumococcal conjugate vaccine 
and pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6 ed. Philadelphia: WB Saunders; 2013. p. 504-41. 
6. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization 
and invasion. Nat Rev Microbiol. 2018;16(6):355-67. 7. Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L. Streptococcus 
pneumoniae serotype 19A: worldwide epi[INVESTIGATOR_623]. Expert Rev Vaccines. 2017;16(10):1007- 27. 
8. Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans. Clin Microbiol Infect. 2012;[ADDRESS_28818] 5:15-24. 
9. Cafiero -Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. The full benefits of adult 
pneumococcal vaccination: A systematic review. PLoS One. 2017;12(10):e0186903. 10. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal 
infection in adults. Cochrane Database Syst Rev. 2013(1):CD000422. 
11. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine. 2004;22(2 3-24):3214-24. 
12. Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 years. 
Expert Opin Biol Ther. 2018;18(1):7-17. 
13. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the 
seven -valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501-8. 
14. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J M ed. 2003;348(18):1737-46. 
15. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and 
immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern [LOCATION_004] Kaiser Permanente Vaccine Study Center Grou p. Pediatr Infect Dis J. 2000;19(3):187-95. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 67 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page [ADDRESS_28819] acute otitis media. N Engl J Med. 2001;344(6):403-9. 
17. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of 
heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810-5. 
18. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and 
safety of seven -valent conjugate pneumococcal vaccine in American Indian children: group 
randomised trial. Lancet. 2003;362(9381):355- 61. 
19. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine -
valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo- controlled trial. Lancet. 2005;365(9465):1139-
46. 
20. Tregnaghi MW, Saez -Llorens X, Lopez P, Abate H, Smith E, Posleman A, et al. Efficacy 
of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD- CV) in 
young Latin American children: A double-blind randomized controlled trial. PLoS Med. 
2014;11(6):e1001657. 
21. Miller E, Andre ws NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype 
replacement 4 years after seven -valent pneumococcal conjugate vaccination in England and 
Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760-8. 22. Flasche S, Van Hoek A J, Goldblatt D, Edmunds WJ, O'Brien KL, Scott JA, et al. The 
Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining 
Herd Immunity in High -Income Countries. PLoS Med. 2015;12(6):e1001839. 
23. Wroe PC, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, et al. 
Pneumococcal carriage and antibiotic resistance in young children before 13- valent conjugate 
vaccine. Pediatr Infect Dis J. 2012;31(3):249-54. 
24. Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype 
replacement. Lancet Infect Dis. 2019;19(6):e213-e20. 25. Stockmann C, Ampofo K, Pavia AT, Blaschke AJ, Mason EO, Presson AP, et al. Clinical 
and Epi[INVESTIGATOR_29485]. Clin Infect Dis. 2016;63(5):619-26. 
26. Jones CH, Zhang G, Nayerhoda R, Beitelshees M, Hill A, Rostami P, et al. Comprehensive 
vaccine design for commensal disease progression. Sci Adv. 2017;3(10):e1701797. 
27. Freedman MS, Hunter P, Ault K, Kroger A. Advisory Committee on Immunization 
Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - [LOCATION_002], 2020. MMWR Morb Mortal Wkly Rep. 2020;69(5):133-5. 
28. Rüggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, et al. 
Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675-84. 
29. Newcombe RG. Two -sided confidence intervals for the single proportion: comparison of 
seven methods. Stat Med . 1998;17(8):857-72. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 68 of 70
[COMPANY_011]  Pasteur PSK00009  
515 - SP0202 
 
 
Confidential/Proprietary Information  
Page 69 of 69 12 Sponsor Signature [CONTACT_29564]/Proprietary Information 
PSK00009
Protocol Version 3.[ADDRESS_28820] Name
[CONTACT_29565]
-
-
-
Approver Name [CONTACT_1782]
(Universal Time)Reason for Signature
[CONTACT_29566]
-
-
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
PSK00009
Protocol Version 3.0
515 - SP0202
Page 70 of 70
